Shopping Cart
Remove All
Your shopping cart is currently empty
Zenocutuzumab (Synonyms: R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128)
Catalog No. T76948 Copy Product Info
Purity: 97%
🥰Excellent
Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.
Zenocutuzumab
Copy Product Info🥰Excellent
Catalog No. T76948
Synonyms R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128
Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.
Zenocutuzumab
Cas No. 1969309-56-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $396 | In Stock | In Stock | |
| 5 mg | $1,190 | - | In Stock | |
| 10 mg | $1,880 | - | In Stock | |
| 25 mg | $2,830 | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement. |
| In vitro | Zenocutuzumab (MCLA-128) (0.001-1000 nM, treated for 96 hours) inhibits the growth of lung and breast cancer cell lines. [1] Zenocutuzumab (0.1-1000 nM, treated for 24 hours) induces apoptosis and triggers expression of markers of cell cycle arrest in lung and breast cancer cell lines by inhibiting phosphorylation of HER3 and AKT. [1] |
| In vivo | Zenocutuzumab (2.5-25 mg/kg, intraperitoneal injection once weekly for 28 days) significantly reduced tumor growth and triggered tumor shrinkage and even regression. [1] |
| Synonyms | R040517, R 040517, PB4188, PB 4188, MCLA-128, MCLA128 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | ERBB2/HER2/CD340 |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1969309-56-5 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Zenocutuzumab | purchase Zenocutuzumab | Zenocutuzumab cost | order Zenocutuzumab | Zenocutuzumab in vivo | Zenocutuzumab in vitro | Zenocutuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.